Substantia Nigra Pars Compacta Dopaminergic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Description: The primary dopaminergic neuron population in the substantia nigra pars compacta (SNc), the neuronal population most vulnerable in Parkinson's disease.
The substantia nigra pars compacta (SNc) contains dopaminergic neurons that project to the striatum, forming the nigrostriatal pathway. These neurons are uniquely vulnerable to degeneration in Parkinson's disease, leading to the characteristic motor symptoms of the disorder.
¶ Location and Connectivity
- Region: Midbrain, substantia nigra pars compacta
- Projections: Dorsal striatum (amen andput caudate)
- Neurotransmitter: Dopamine
- Innervation pattern: Tonically active, pace-making firing
- Neuromelanin-containing: Brown-black pigment in human neurons
- Large cell bodies: 20-30 μm diameter
- Extensive dendritic arborization
- High iron content
- Pacemaker activity: Autonomous Ca2+ influx through L-type channels
- Mitochondrial complex I deficiency: ROS production
- Neuromelanin accumulation: Iron sequestration
- High oxidative metabolism: Large ATP demands
- Long axons: Extensive trafficking burden
- Neuroinflammation: Microglial activation
- Alpha-synuclein pathology: Lewy body formation
- Iron dysregulation: Fenton chemistry
- Metabolic stress: Impaired glucose metabolism
- Selective vulnerability: SNc > ventral tegmental area
- Pattern: Dorsolateral SNc affected first
- Cell loss: 50-70% at diagnosis
- Progression: Spreads to other brain regions
- Lewy bodies: Intracellular inclusions of alpha-synuclein
- Lewy neurites: Dysregulated neurites
- Location: Perikarya and processes
- Formation: Early event in pathogenesis
- iPSC-derived dopaminergic neurons: Patient and control lines
- Primary midbrain cultures: Rodent and human
- Organoid models: Brain organoids with SNc-like regions
- MPTP toxicity: Chemical model
- 6-OHDA lesions: Selective catecholamine depletion
- Alpha-synuclein models: Viral and transgenic
- LRRK2 models: Genetic models
- MAO-B inhibitors: Selegiline, rasagiline
- Calcium channel blockers: Isradipine
- Iron chelators: Deferoxamine
- GDNF delivery: Neurorestorative approaches
- ** embryonic dopamine neurons**: Historical trials
- iPSC-derived neurons: Current approaches
- Autologous transplantation: Patient-specific lines
The study of Substantia Nigra Pars Compacta Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Selective vulnerability of SNc neurons (2011)
- Neuromelanin and PD (2019)
- iPSC models of SNc neurons (2018)
- Parkinson's disease neuroprotection (2021)